The Immunoexpression of YAP1 and LATS1 Proteins in Clear Cell Renal Cell Carcinoma: Impact on Patients’ Survival

Table 1

Correlations between clinical-pathological characteristics of the patients with clear cell renal cell carcinoma (ccRCC) and YAP1 immunoreactivity in the cancer cells (determined by immunohistochemistry).

(a)

Qualitative parameters	Number of patients	YAP1 nuclear immunoreactivity in ccRCC			YAP1 cytoplasmic immunoreactivity in
		cells (expressed as scores)			ccRCC cells (expressed as scores)
		0-1; (%)	2-3; (%)	value	0; (%)	1-2; (%)	value
Total	54	19; (35.2)	35; (64.8)		41; (75.9)	13 (24.1)
Men	31	11; (35.5)	20; (64.5)	1.0000	24; (77.4)	7 (22.6)	1.0000
Women	23	8; (34.8)	15; (65.2)		17; (73.9)	6; (26.1)
Depth of invasion
T1 + T2	42	13; (31.0)	29; (69.0)	0.3066	30; (71.4)	12; (28.6)	0.2538
T3	12	6; (50.0)	6; (50.0)		11; (91.7)	1; (8.3)
Fuhrman grade
G1 + G2	42	12; (28.6)	30; (71.4)	0.0867	34; (81.0)	8; (19.0)	0.1340
G3	12	7; (58.3)	5; (41.7)		7; (58.3)	5; (41.7)
Distant metastases
M0	47	16; (34.0)	31; (66.0)	0.6866	35; (74.5)	12; (25.5)	1.0000
M1	7	3; (42.9)	4; (57.1)		6; (85.7)	1; (14.3)

(b)

Quantitative parameters			value				value
Age	−0.08		0.5494		−0.01		0.9256
Tumor size	−0.08		0.5544		0.06		0.6581

The scores evaluate percentage cells with YAP1 nuclear immunoreactivity. The scores assess intensity of YAP1 cytoplasmic IHC reactions, both described in Methods. Fisher exact test. Spearman’s correlation.